--- title: "Enovis (ENOV) Following CMS Reversal, Why The Valuation Story Is Back In Focus" type: "News" locale: "en" url: "https://longbridge.com/en/news/291988466.md" description: "Enovis (ENOV) stock surged 23.29% in seven days after CMS reversed planned reimbursement cuts for its noninvasive bone growth stimulators. Despite this positive regulatory shift, the company faces long-term headwinds, with shareholder returns declining significantly over one and three years. Analysts currently view ENOV as undervalued, estimating a fair value of $42.30 against its recent close of $25.52, citing potential for margin expansion through new technologies like Arvis, though integration risks remain." datetime: "2026-07-07T23:59:50.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/291988466.md) - [en](https://longbridge.com/en/news/291988466.md) - [zh-HK](https://longbridge.com/zh-HK/news/291988466.md) generator: "portal-rs" --- # Enovis (ENOV) Following CMS Reversal, Why The Valuation Story Is Back In Focus The sharp move in Enovis (ENOV) stock was triggered by the Centers for Medicare & Medicaid Services reversing planned reimbursement cuts on its noninvasive bone growth stimulators, a regulatory decision closely watched by investors. See our latest analysis for Enovis. That regulatory reversal has come after a tougher stretch for Enovis, with the stock showing a 1 year total shareholder return that declined 26.54% and a 3 year total shareholder return that declined 60.70%. At the same time, the recent 7 day share price return of 23.29% suggests short term momentum is building from a lower base. If you are looking for more ideas in healthcare and medical technology after Enovis, this is a good moment to see what else is moving through 40 healthcare AI stocks Enovis has a broad medical technology platform and fresh regulatory support, yet the stock is coming off years of weak shareholder returns even after the recent jump. Is this a quality business still offered at a fair price, or not? ## Most Popular Narrative: 39.7% Undervalued Enovis last closed at $25.52, while the most followed valuation narrative points to a fair value of $42.30, creating a wide gap investors are trying to understand. > *Enovis's focus on launching next-generation, enabling technologies such as Arvis (augmented reality navigation) and ongoing pipeline innovation in hips, knees, and shoulders positions the business to capture premium pricing, gain market share, and expand adjusted EBITDA margins as global healthcare expenditure prioritizes surgical innovation and mobility outcomes.* Read the complete narrative. Want to see what sits behind that valuation gap? The narrative leans heavily on compounding revenue, higher margins, and a richer earnings multiple. The exact mix might surprise you. **Result: Fair Value of $42.30 (UNDERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, investors still need to factor in the risk that Enovis' acquisition integrations and any further delays to platforms like Arvis could undercut the bullish valuation story. Find out about the key risks to this Enovis narrative. ## Next Steps If the mix of optimism and caution around Enovis has you thinking, it is worth checking the data yourself and moving quickly while sentiment is shifting. To see what investors are highlighting as potential positives right now, review the 3 key rewards. ## Looking for more investment ideas beyond Enovis? If Enovis has sharpened your focus, do not stop here. Use the Simply Wall St screener to spot other opportunities that could fit your approach. - Target reliable cash generators by reviewing companies in the solid balance sheet and fundamentals stocks screener (47 results). - Hunt for potential value opportunities before the crowd catches on with the 45 high quality undervalued stocks. - Prioritize consistency and capital protection by scanning the 74 resilient stocks with low risk scores. *This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.* ### Valuation is complex, but we're here to simplify it. Discover if Enovis might be undervalued or overvalued with our detailed analysis, featuring **fair value estimates, potential risks, dividends, insider trades, and its financial condition.** Access Free Analysis ### Related Stocks - [ENOV.US](https://longbridge.com/en/quote/ENOV.US.md) ## Related News & Research - [CMS Energy Stock: Is Wall Street Bullish or Bearish?](https://longbridge.com/en/news/296209904.md) - [Consumers Energy Invests in Reliability Upgrades to Secure the Grid for Michigan Customers | CMS Stock News](https://longbridge.com/en/news/296506106.md) - [LEAD Launch Leaves Accountable Care Technology Buyers Little Time for a Wrong Decision, Q3 Study](https://longbridge.com/en/news/296106866.md) - [Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says](https://longbridge.com/en/news/296227811.md) - [Mitsubishi UFJ Trust & Banking Corp Acquires 76,836 Shares of PepsiCo, Inc. $PEP](https://longbridge.com/en/news/296697080.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**